CoChat

Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development

Burt, Tal, Vuong, Le Thuy, Baker, Elizabeth, Young, Graeme C., McCartt, A. Daniel, Bergstrom, Mats, Sugiyama, Yuichi, Combes, Robert · 2018 · Alternatives to Laboratory Animals

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

Phase 0 approaches, including microdosing, involve the use of sub-therapeutic exposures to the tested drugs, thus enabling safer, more-relevant, quicker and cheaper first-in-human (FIH) testing. These approaches also have considerable potential to limit the use of animals in human drug development. Recent years have witnessed progress in applications, methodology, operations, and drug development culture. Advances in applications saw an expansion in therapeutic areas, developmental scenarios and scientific objectives, in, for example, protein drug development and paediatric drug development. In the operational area, the increased sensitivity of Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS), expansion of the utility of Positron Emission Tomography (PET) imaging, and the introduction of Cavity Ring-Down Spectroscopy (CRDS), have led to the increased accessibility and utility of Phase 0 approaches, while reducing costs and exposure to radioactivity. PET has extended the application of microdosing, from its use as a predominant tool to record pharmacokinetics, to a method for recording target expression and target engagement, as well as cellular and tissue responses. Advances in methodology include adaptive Phase 0/Phase 1 designs, cassette and cocktail microdosing, and Intra-Target Microdosing (ITM), as well as novel modelling opportunities and simulations. Importantly, these methodologies increase the predictive power of extrapolation from microdose to therapeutic level exposures. However, possibly the most challenging domain in which progress has been made, is the culture of drug development. One of the main potential values of Phase 0 approaches is the opportunity to terminate development early, thus not only applying the principle of 'kill-early-kill-cheap' to enhance the efficiency of drug development, but also obviating the need for the full package of animal testing required for therapeutic level Phase 1 studies. Finally, we list developmental scenarios that utilised Phase 0 approaches in novel drug development.

Overview

Integrity signals

Registry

Crossref · 10.1177/026119291804600603

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 69 references

Research works printed but not linked: 7

  1. Vuong L.T., 2015, Future Science OA, 2, 1
  2. Wagner C.C., 2008, Current Opinion in Drug Discovery & Development, 11, 104
  3. LappinG., WarringtonS., HoneybourneD., SangheraD., DowenS., ListerN., IslamK. & LociuroS. (2007). Concentrations of AR-709 in plasma and key compartments of the lungs after microdosing. [Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA].
  4. Carpenter A.P., 2009, Quarterly Journal of Nuclear Medicine & Molecular Imaging, 53, 387
  5. Combes R., 2006, ATLA, 34, 621
  6. BéruBé K., 2009, ATLA, 37, 89
  7. Bailey J., 2014, ATLA, 42, 181

Cited by

See all 18

Metadata

Authors
Burt, T., Vuong, L. T., Baker, E., Young, G. C., McCartt, A. D., Bergstrom, M., Sugiyama, Y., & Combes, R.
Affiliations
  • Burt Consultancy, LLC, Durham, NC, USA;
  • LTV Consulting, Davis, CA, USA;
  • Physicians Committee for Responsible Medicine (US)
  • GlaxoSmithKline (United Kingdom) (GB)
  • Lawrence Livermore National Laboratory (US)
  • Department of Pharmacology and PET-centre, Uppsala University, Uppsala, Sweden
  • RIKEN (JP)
  • Independent Consultant, Norwich, UK
Corresponding author
Burt, Tal
Venue
Alternatives to Laboratory Animals
Published
2018-12
Volume
46
Issue
6
Pages
335-346
ISSN
  • 0261-1929 (ISSN-L)
  • 2632-3559
OpenAlex
W2938039109
Cited by
18
References
69
Citations by year
2026: 1 · 2024: 1 · 2023: 4 · 2022: 1 · 2021: 3 · 2020: 6 · 2019: 2
FWCI
2.28
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Alternatives to Laboratory Animals (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
Keywords
microdosing, 3Rs, animal testing reduction, positron emission tomography, target engagement, LC-MS/MS, cavity ring-down spectroscopy, pediatric drug development, drug development efficiency
MeSH terms
Drug Development, Animals, Animal Testing Alternatives, Animal Welfare, Chromatography, Liquid, Humans, Animal Experimentation, Positron-Emission Tomography, Tandem Mass Spectrometry

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development. https://app.cochat.ai/papers/10.1177/026119291804600603
The paper
Burt, T., Vuong, L. T., Baker, E., Young, G. C., McCartt, A. D., Bergstrom, M., Sugiyama, Y., & Combes, R. (2018). Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development. Alternatives to Laboratory Animals. https://doi.org/10.1177/026119291804600603

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.